Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
57 hedge funds and large institutions have $129M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 30 increasing their positions, 9 reducing their positions, and 6 closing their positions.
233% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 9
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
4% more funds holding
Funds holding: 55 → 57 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less capital invested
Capital invested by funds: $140M → $129M (-$11.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.35M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.8M |
| 3 |
BlackRock
New York
|
+$2.59M |
| 4 |
JP Morgan Chase
New York
|
+$2.51M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$891K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$68.2M |
| 2 |
ACM
Ativo Capital Management
Chicago,
Illinois
|
-$1.13M |
| 3 |
Daiwa Securities Group
Tokyo,
Japan
|
-$829K |
| 4 |
Millennium Management
New York
|
-$727K |
| 5 |
Bessemer Group
Woodbridge,
New Jersey
|
-$373K |
RETA Hedge Fund Activity: Q2 2017 in Review
57 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q2 2017, worth a combined $129M — down 8% from $140M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new RETA positions and 6 closed out — a net gain of 2 holders — while 30 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $4.35M. The largest seller was Novo Holdings A/S, cutting an estimated $68.2M.
- 57 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q2 2017, up from 55 in Q1 2017.
- Funds reported $129M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q2 2017, down 8% quarter-over-quarter.
- 8 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q2 2017 and 6 closed out, a net change of +2 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q2 2017 was Fidelity Investments, an estimated $4.35M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q2 2017 was Novo Holdings A/S, an estimated $68.2M sold.
Based on aggregated 13F filings for Q2 2017.